Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response

American Heart Journal
Richard L PageAzimilide Supraventricular Arrhythmia Program (ASAP) Investigators

Abstract

Azimilide is a novel classification III antiarrhythmic agent that blocks both I(Kr)and I(Ks)and shows evidence of efficacy in patients with atrial fibrillation or flutter. Its effect on paroxysmal supraventricular tachycardia (PSVT) has not been reported. One hundred ninety-three patients with symptomatic PSVT were enrolled in 4 double-blind, randomized, placebo-controlled clinical trials with almost identical trial design (supraventricular arrhythmia-1 [SVA-1], SVA-2, SVA-3, and SVA-4), performed as a separate stratum of studies that also included a stratum of patients with atrial fibrillation or flutter. Patients received oral azimilide (100 mg in SVA-1 and SVA-3, 35 or 75 mg in SVA-2, and 125 mg in SVA-4) or matching placebo twice daily for 3 days (loading period), followed by once-daily dosing (maintenance period). The primary outcome variable was the first recording of a symptomatic supraventricular arrhythmia (either PSVT, atrial fibrillation, or atrial flutter) recorded on a transtelephonic electrocardiographic event recorder. The duration of study was 270 days in SVA-1 and SVA-2 and 180 days in SVA-3 and SVA-4. Combined analysis results of the PSVT stratum from the 4 studies showed a dose-response relationship in prolon...Continue Reading

Citations

May 14, 2005·Expert Review of Cardiovascular Therapy·Mark Carlson
Jan 25, 2007·Expert Opinion on Investigational Drugs·Kristen K Patton, Richard L Page
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
Mar 13, 2009·Expert Opinion on Investigational Drugs·Mohan N Viswanathan, Richard L Page
Oct 22, 2008·The American Journal of Cardiology·Emily ConwayPeter R Kowey
Nov 8, 2005·Progress in Cardiovascular Diseases·Robert N Goldstein, Bruce S Stambler
Dec 23, 2003·Current Opinion in Cardiology·Mazhar H Khan
Mar 5, 2003·Circulation·Richard L PageUNKNOWN Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators
Aug 13, 2004·Current Cardiology Reports·Deborah L Wolbrette
Mar 31, 2015·The Cochrane Database of Systematic Reviews·Carmelo Lafuente-LafuenteJoël Belmin
Sep 5, 2019·The Cochrane Database of Systematic Reviews·Lucie ValemboisCarmelo Lafuente-Lafuente
Sep 21, 2013·Current Cardiology Reports·Kapil Kumar, Peter J Zimetbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.